Theravance Biopharma (TBPH) Tops Q2 EPS by 44c, Revenues Beat

Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.76), $0.44 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $23.75 million versus the consensus estimate of $10.67 million.

Rick E Winningham, Chairman and Chief Executive Officer, commented: "We have made exciting progress across our portfolio. Positive data from the TD-1473 Phase 1b study in ulcerative colitis and TD-9855 Phase 2 study in nOH provide strong clinical rationale for the progression into registrational programs, and with regulatory dialogues recently completed, each program now has a clear path into late-stage studies. For YUPELRI™, our brand name for revefenacin, we and our partner Mylan are finalizing launch readiness activities in anticipation of a potential FDA approval later this year. In our early stage pipeline, we are preparing to advance TD-8236, our novel inhaled JAK inhibitor for serious respiratory diseases, into the clinic. These recent pipeline advancements along with a strong balance sheet and emerging cash flows from Trelegy Ellipta position us to continue to deliver growth across our business – from research to commercial – to drive value for shareholders and maximize the impact we can make on patients' lives."

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• CrowdStrike posts record ARR growth, raises full-year outlook
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance